CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
CG Oncology will present first results from the CORE-008 Cohort CX Phase 2 trial at the American Urological Association (AUA) 2026 Annual Meeting, evaluating intravesical combination therapy in high-risk BCG-exposed and BCG-unresponsive patients. The company will also exhibit at booth #3051, providing an opportunity for attendees to learn more about its clinical development program and commitment to advancing innovative therapies for bladder cancer.
Key figures
- Drug Name
- Cretostimogene Grenadenorepvec
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.